RayKnowChina Research Map
Shortlist0

RecruitingNasopharyngeal carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Nituzumab (Taixinsheng ®) A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by Sichuan Cancer Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05508347, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Nasopharyngeal carcinoma 2018 AJCC (Eighth Edition) staging: t2-4n2m0 (metastatic lymph nodes have one of the following risk factors: the shortest length of the largest lymph node is ≥ 3cm or the lymph node is liquefied and necrotic or the lymph node envelope is invaded) or t1-4n3m0.

    Inclusion criterion 4

  3. Subjects who have received other drug tests in the past 1 month.

    Exclusion criterion 7

  4. Hemoglobin (Hgb) ≥ 90 g / L, white blood cell (WBC) ≥ 4 × 109 / L, platelet (PLT) ≥ 90 × 109 /L.

    Inclusion criterion 10

    Liver function: ALT and / or ast < 1.5 times the upper limit of normal value (ULN), and TBIL < 1.5 times the upper limit of normal value (ULN).

    Inclusion criterion 11

  5. Known to be infected with HIV virus or active viral hepatitis.

    Exclusion criterion 12

  6. Pregnant or lactating women and women of childbearing age who refuse contraception during the treatment observation period.

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; day-to-day activity level; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05508347, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion criteria:

  • Voluntarily participate and sign the informed consent in writing.
  • Age: 18-70 years old, gender is not limited.
  • Nasopharynx squamous cell carcinoma diagnosed by histopathology.
  • Nasopharyngeal carcinoma 2018 AJCC (Eighth Edition) staging: t2-4n2m0 (metastatic lymph nodes have one of the following risk factors: the shortest length of the largest lymph node is ≥ 3cm or the lymph node is liquefied and necrotic or the lymph node envelope is invaded) or t1-4n3m0.
  • Immunohistochemistry: EGFR (+).
  • The primary tumor can be measured.
  • Kaplan score > 70.
  • Survival expectation ≥ 6 months.
  • Women in childbearing period should ensure to take effective contraception during the study period.
  • Hemoglobin (Hgb) ≥ 90 g / L, white blood cell (WBC) ≥ 4 × 109 / L, platelet (PLT) ≥ 90 × 109 /L.
  • Liver function: ALT and / or ast < 1.5 times the upper limit of normal value (ULN), and TBIL < 1.5 times the upper limit of normal value (ULN).

Renal function: serum creatinine < 1.5 times the upper limit of normal value (ULN); Creatinine clearance rate shall not be lower than 60ml / min.

Exclusion criteria:

  • There is evidence of distant metastasis.
  • The primary tumor or lymph node has been treated surgically (except biopsy).
  • Patients with primary focus or lymph nodes who have received radiotherapy.
  • Those who have received epidermal growth factor targeted therapy.
  • The primary lesion has received chemotherapy or immunotherapy.
  • Have had other malignant tumors (except non melanoma skin cancer or cervical carcinoma in situ).
  • Subjects who have received other drug tests in the past 1 month.
  • > grade I peripheral neuropathy.
  • Pregnant or lactating women and women of childbearing age who refuse contraception during the treatment observation period.
  • Those with severe allergic history or special constitution.
  • A history of severe lung or heart disease.
  • Known to be infected with HIV virus or active viral hepatitis.
  • Received live vaccine within 30 days of the planned start of study drug treatment.
  • Those who refuse or cannot sign the informed consent form.
  • Drug or alcohol addicts.
  • Persons with personality or mental illness, without or with limited capacity for civil conduct.

Quoted from ClinicalTrials.gov, NCT05508347, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05508347, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05508347